A A Hurwitz
Affiliation: University of California
- Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinomaA A Hurwitz
Howard Hughes Medical Institute, Cancer Research Laboratory, University of California, Berkeley 94720, USA
Int J Cancer 77:107-13. 1998....
- CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinomaA A Hurwitz
Howard Hughes Medical Institute, Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA
Proc Natl Acad Sci U S A 95:10067-71. 1998..In addition, these results also support the idea that the most effective and synergistic vaccine strategy targets treatments that enhance T cell priming at the level of host-derived antigen-presenting cells...
- Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitisA A Hurwitz
Department of Molecular and Cellular Biology, University of California, Berkeley 94720, USA
J Neuroimmunol 73:57-62. 1997..These data suggest that CTLA-4-mediated inhibitory signals can regulate the clinical severity and histologic parameters of neuroautoimmune disease...
- Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockadeA A Hurwitz
Cancer Research Laboratory, University of California, Berkeley 94720, USA
Cancer Res 60:2444-8. 2000..These findings demonstrate that this combinatorial treatment can elicit a potent antiprostate response and suggest potential of this approach for treatment of prostate cancer...
- Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapyA van Elsas
Howard Hughes Medical Institute and Cancer Research Lab, University of California, Berkeley, CA 94720, USA
J Exp Med 194:481-9. 2001..Our data demonstrate that therapeutic autoreactive CD8(+) T cell responses can effectively be generated in tumor-bearing mice and stresses the value of studying tumor immunity in a therapeutic rather than a prophylactic setting...